Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.8%) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Trading Halts

Raymond James Downgrades Dipexium Pharmaceuticals (DPRX) to Market PerformOctober 26, 2016 7:33 AM Dipexium Pharma (DPRX) Resumes Trading Following LUDP HaltOctober 25, 2016 12:35 PM Dipexium Pharma (DPRX) Halted LUDPOctober 25, 2016 12:28 PM Feltl & Co Downgrades Dipexium Pharmaceuticals (DPRX) to HoldOctober 25, 2016 11:52 AM Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex® in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized WoundOctober 25, 2016 7:01 AM Dipexium Pharma (DPRX) trading halted with news pendingOctober 25, 2016 6:56 AM